Biosyent (RX) Planet MicroCap Showcase: VEGAS 2025 summary

Conference attendance and engagement

• Afternoon sessions saw nearly full attendance, indicating strong participant engagement.

• Attendees represented a diverse set of companies, with some arriving later in the day.

Business overview and strategy

• Operates as a profitable, growth-stage Canadian specialty pharmaceutical company, generating 90% of revenue domestically and 10% internationally.

• Focuses on licensing or acquiring late-stage, differentiated products globally and commercializing them in Canada.

• Maintains two sales teams targeting both general practitioners and specialists, with products present in 98% of Canadian pharmacies and 250 hospitals.

• Prioritizes long-term deals, often extending relationships beyond 15 years.

Financial performance and shareholder returns

• Achieved CAD 35 million in revenue, over CAD 9 million EBITDA, CAD 0.62 EPS, and 21% ROE last year.

• Revenue grew by two-thirds and EPS doubled since 2019, with consistent profitability for 15 years.

• Strong balance sheet with CAD 26 million in cash and no debt; last equity raise was in 2002.

• Actively returns capital to shareholders through buybacks and dividends, with no dilutive share options since 2019.

• Management and insiders own 26%, and 75% of employees are shareholders.